FINNENCE ▪ THE WIRE FILE
THE WIRE · № 62514
News■ Unclear/unknown
Angel Aligner ersetzt in Europa die „Torque Ridges" durch „Pressure Points"
KINDNews
DIRECTION■ Unclear/unknown
SOURCES1
ENTITIES1
STORY SIZESTANDALONE
FIRST SEEN2026-10-02 18:56 UTC
LAST UPDATE2026-10-02 18:56 UTC
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
Product feature update from listed aligner maker; incremental, no financial figures given.
Angel Aligner swaps torque ridges in Europe
CATALYST TO WATCH
European adoption and sales disclosure
MAIN RISK
Feature-level news; no volume data
FULL DISPATCH
Neue Funktion verbessert die Drehmomentsteuerung durch die Nutzung von Druckpunkten und Trimline-Optionen SAN CLEMENTE, Kalifornien, 2. Oktober 2026 /PRNewswire/ -- Angelalign Technology Inc. (6699.HK) („Angel") http://www.angelaligner.com, ein weltweit führender Pionier im Bereich der...
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
AFFECTEDHealthcare
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→CORRELATIONshares Healthcare
Lilly's Jaypirca (pirtobrutinib), the first-and-only approved non-covalent BTK inhibitor, receives expanded indication from U.S. FDA for certain patients with previously untreated CLL/SLL2026-10-02 19:05 UTC
Lilly's Jaypirca (pirtobrutinib), the first-and-only approved non-covalent BTK inhibitor, receives expanded indication from U.S. FDA for certain patients with previously untreated CLL/SLL2026-10-02 19:05 UTC
→CORRELATIONshares Healthcare
NeuroSense Provides Update on Nasdaq Listing Compliance2026-10-02 20:15 UTC
NeuroSense Provides Update on Nasdaq Listing Compliance2026-10-02 20:15 UTC
←CORRELATIONshares Healthcare
New Phase 3 trial: Trial to Evaluate ALN-CIDEB in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) — Regeneron Pharmaceuticals2026-10-02 12:00 UTC
New Phase 3 trial: Trial to Evaluate ALN-CIDEB in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) — Regeneron Pharmaceuticals2026-10-02 12:00 UTC
←CORRELATIONshares Healthcare
New Phase 3 trial: A Study to Evaluate the Efficacy and Safety of Proximod in Patients With Rheumatoid Arthritis — Jiankuan (Suzhou) Biotechnology Company Limited2026-10-02 12:00 UTC
New Phase 3 trial: A Study to Evaluate the Efficacy and Safety of Proximod in Patients With Rheumatoid Arthritis — Jiankuan (Suzhou) Biotechnology Company Limited2026-10-02 12:00 UTC
←CORRELATIONshares Healthcare
New Phase 3 trial: SYNCHRONIZE®-START- A Study to Test Whether Survodutide Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight — Boehringer Ingelheim2026-10-02 12:00 UTC
New Phase 3 trial: SYNCHRONIZE®-START- A Study to Test Whether Survodutide Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight — Boehringer Ingelheim2026-10-02 12:00 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.